Shionogi Presents New Ensitrelvir Clinical and Real-World Data Reinforcing Potential Across COVID-19 Populations at ESWI 2023

OSAKA, Japan, September 18, 2023--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") will present two late-breaking posters at the European Scientific Working Group on Influenza and other Respiratory Viruses’ (ESWI), 9th Influenza Conference, highlighting data suggesting the potential of its investigational oral antiviral ensitrelvir on symptoms associated with long COVID and in high-risk COVID-19 hospitalized patients with sign

Related Keywords

Japan ,Osaka ,South Korea ,Vietnam ,Republic Of ,Japanese ,Isao Teshirogi ,Andreas Karas ,Shionogi Europe ,Hokkaido University ,National Health Service ,International Health Regulations ,Drug Administration ,Head Office ,Ensitrelvir Clinical Development Program ,Shionogi Co Ltd ,Center Case Series ,World Health Organization ,Ministry Of Health ,European Scientific Working Group On Influenza ,Emergency Committee ,Centers For Disease ,Chief Executive Officer ,European Scientific Working Group ,Respiratory Viruse ,Influenza Conference ,Fast Track ,Vice President ,Medical Affairs ,Rinku General Medical Centre ,Ensitrelvir Clinical Development ,Respiratory Infections ,Viral Emergencies ,Medicines Patent Pool ,Post Hoc Analysis ,Medicine Vol ,Treatment Option ,After Remdesivir ,Hospitalized Patients ,Health Service ,Disease Control ,Shionogi ,Covid ,Investigational Drug ,Ensitrelvir ,